Business, energy, technology, markets and global industry news from Business News Today

tyrosine kinase inhibitors

PharmaDeviceNews tyrosine kinase inhibitors
Representative image of generic oncology tablets in a clinical pharmacy setting, illustrating Dr. Reddy’s Laboratories’ Bosutinib 400mg launch in the United States and its potential impact on chronic myelogenous leukemia drug access.
Pharma & Biotech

Could Dr. Reddy’s 180-day Bosutinib window change the economics of CML treatment?

Read how Dr. Reddy’s Bosutinib 400mg launch could reshape U.S. CML generics, pricing and oncology access.

Read More
Representative image of leukemia drug research as Enliven Therapeutics’ ELVN-001 data put chronic myeloid leukemia treatment, Phase 3 trial planning, and targeted oncology therapy under sharper focus.
Pharma & Biotech

Enliven Therapeutics moves ELVN-001 closer to Phase 3 as CML drug competition intensifies

Find out how Enliven Therapeutics’ ELVN-001 data and FDA alignment could reshape chronic myeloid leukemia drug development.

Read More
Representative image: GSK’s $10.6 billion Nuvalent deal puts precision lung cancer therapies in focus as Big Pharma races to secure late-stage oncology assets.
Pharma & Biotech

Why GSK is paying $10.6bn for Nuvalent as targeted lung cancer drugs near FDA decisions

GSK is betting $10.6B on Nuvalent’s lung cancer drugs. The payoff now depends on FDA decisions, labels and oncology launch execution.

Read More